FORMA, University of Oxford collaborate to develop deubiquitinating enzyme inhibitors to treat neuro degenerative diseases

FORMA Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neuro

More From BioPortfolio on "FORMA, University of Oxford collaborate to develop deubiquitinating enzyme inhibitors to treat neuro degenerative diseases"